Although there are safety concerns such as the potential risk of new-onset diabetes [11–13], several meta-analyses have demonstrated that PCSK9 inhibitors showed better effects in reducing LDL-C levels and improving clinical benefits than other lipid-lowering agents for the secondary prevention of cardiovascular disease [14, 15]. Here, PCSK9 is linked to cardiovascular disorder.